MIAS Pharma holds an MIA for Batch Certification of Commercial Medicinal Products and provides integrated contract QP, QA and RP Services which our clients can utilise as a low cost, low risk stepping stone into the EU market.
At MIAS, we offer expert WDA support to help our clients navigate the regulatory requirements and ensure compliance with all relevant guidelines.
In the UK, no batch of medicinal product can be released for sale or supply prior to certification by a Qualified Person (QP).
& QP Services.
MIAS Pharma Ltd was set up in 2016 to enable Pharma / Bio-Pharma companies to manufacture and import products into the EU / EEA and the UK in a compliant manner, at optimal cost, with no significant investment in licence application activities or office / personnel costs.
It is now a multi million pound business with customers in UK, US, Australia-Asia, Europe, and Ireland.
Customers are small to medium Pharma / Bio-Pharma companies that look to enter the EU market but do not have required Manufacturing and Importation licence or the Quality/Regulator expertise to comply with complex EU regulations.
MIAS Pharma delivers two main solutions:
A licensing framework to enable pharmaceutical importation and batch certification (required before each batch of a medicine can be made available in the EU/EEA marketplace)
Qualified Person (QP) services to oversee the release of investigational medicinal product for Clinical Trials and commercial product to the market.
WE LET THE NUMBERS DO THE TALKING
+ Active Trials
+ Commercial Products
+ Years
of experience
Company
you should choose
Discover more about our MIAS Pharma services
HAVE TO SAY ABOUT OUR PROFESSIONAL SERVICES
The 2022 revision of Annex 1 of the EU Guidelines to Good Manufacturing Practice (GMP) marked the most significant update to sterile manufacturing guidance in over a decade. With its mandatory enforcement […]
A Responsible Person for Imports (RPi), plays a crucial role in ensuring that products imported into the United Kingdom comply with UK certification and regulatory requirements. This role enables the […]
With the introduction of the QP Oversight of IMPs process by MHRA from 01 Jan 2022 the process of getting product released to trial in the UK has been simplified. […]